Structure--activity relationships of side-chain modified didemnins

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Organic Synthesis

Background:

• Didemnins are a class of marine natural products with potent cytotoxic and antitumor activities.
• Understanding the structure-activity relationships (SAR) of didemnins is crucial for developing new anticancer agents.
• Previous studies have explored synthetic analogues to improve efficacy and reduce toxicity.

Purpose of the Study:

• To synthesize and evaluate the antitumor activity of a novel didemnin B analogue.
• To investigate the impact of a psi[CH2NH] amide bond surrogate on biological activity.
• To contribute to the understanding of side-chain SAR for didemnins.

Main Methods:

• Synthesis of a novel didemnin B analogue incorporating a psi[CH2NH] amide bond surrogate between N-Me-D-Leu7 and Pro8.
• Antitumor activity evaluation using the National Cancer Institute's (NCI-60) tumor cell line screen.
• Comparative analysis of the analogue's activity against didemnin B and other synthetic analogues.

Main Results:

• The novel didemnin B analogue exhibited significant antitumor activity with a GI50 value of 4 nM.
• This activity was comparable to that of the parent compound, didemnin B (GI50 = 13 nM).
• The results support the potential of amide bond surrogates in maintaining or enhancing biological activity.

Conclusions:

• The synthesized didemnin B analogue with a psi[CH2NH] amide bond surrogate is a promising candidate for further anticancer drug development.
• The study provides valuable insights into the SAR of didemnins, particularly concerning the role of the peptide backbone.
• Further research is warranted to explore the therapeutic potential and mechanism of action of this novel analogue.